Patents Examined by Timothy R Rozof
  • Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2C (5-HT)
    Patent number: 11485734
    Abstract: Disclosed are novel small molecules, methods of synthesis of the small molecules, and uses of the small molecules for modulating activity of the human serotonin receptor 2C (5-HT2c), preferably selectively. The small molecules have a substituted beta-carboline core structure, which optionally may be saturated at one or more bonds to provide a dihydro-beta-carboline core or a tetrahydro-beta-carboline core. The small molecules may be administered to treat and/or prevent diseases, disorders, and/or conditions associated with human serotonin receptor 2C (5-HT2C) including psychiatric, mental, and/or neurological diseases, disorders, and conditions such as cognitive impairment, addiction, and obsessive compulsive disorder. The disclosed small molecules also may be administered to treat and/or prevent obesity, for example, via appetite suppression.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: November 1, 2022
    Assignee: Northwestern University
    Inventors: Karl A. Scheidt, Herbert Y. Meltzer, Adam J. Csakai
  • Griseofulvin compound
    Patent number: 11472784
    Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: R1: e.g., a C1-C6 alkyl group; R2: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R3: e.g., a C1-C6 alkyl group.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: October 18, 2022
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Keiji Saito, Katsuyoshi Nakajima, Toru Taniguchi, Osamu Iwamoto, Satoshi Shibuya, Yasuyuki Ogawa, Kazumasa Aoki, Nobuya Kurikawa, Shinji Tanaka, Momoko Ogitani, Eriko Kioi, Kaori Ito, Natsumi Nishihama, Tsuyoshi Mikkaichi, Wataru Saitoh
  • Process for making amino diaryl ethers and amino diaryl ethers hydrochloride salts
    Patent number: 11472771
    Abstract: The present invention relates to a process for making a compound of formula (I) as described herein Formula (I) comprising reducing a compound of formula (II) as described herein with hydrogen in the presence of a palladium catalyst and a solvent wherein the solvent is a polar, aprotic solvent or a C3-C10 alcohol Formula (II). The present invention further relates to a hydrochloride salt and a monohydrochloride salt of the compound of formula (I) as described herein and to a process for making the same Formula (I).
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: October 18, 2022
    Assignee: CELLESTIA BIOTECH AG
    Inventors: Michael Bauer, Uwe Hahn, Erhard Bappert
  • Compositions and methods for treating cannabinoid hyperemesis syndrome with a cannabinoid receptor antagonist
    Patent number: 11471437
    Abstract: Disclosed herein are formulations and methods for reversing one or more symptoms of cannabinoid hyperemesis syndrome (CHS) or one or more symptoms thereof, comprising parenterally administering a CB1 antagonist in an amount sufficient to reverse the CHS or symptom(s).
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: October 18, 2022
    Assignee: Opiant Pharmaceuticals, Inc.
    Inventor: Phil Skolnick
  • Methods
    Patent number: 11471438
    Abstract: Provided are methods of using (1R,5S)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: October 18, 2022
    Assignee: Ethismos Research, Inc.
    Inventor: Anthony McKinney
  • Crystal and salt forms of tricyclic compound and preparation process thereof
    Patent number: 11465995
    Abstract: Provided are a crystal form of a tricyclic compound and a preparation process thereof. Also provided is an application of the crystal form in preparing a drug for treating a disease related to a sphingosine-1-phosphate subtype 1 (S1P1) receptor.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: October 11, 2022
    Assignee: Medshine Discovery Inc.
    Inventors: Peng Zhang, Weidong Li, Lingyun Wu
  • Vaccine containing cancer cells inactivated by photodynamic treatment with metal-based coordination complexes, and immunotherapy method using same
    Patent number: 11464798
    Abstract: A method for treating a tumor in a patient by administering to the patient an immunogenic composition including antigenic material inactivated by treatment with a metal-based coordination complex and electromagnetic radiation, wherein the immunogenic composition is effective to elicit an immune response to the antigenic material in the patient after administration and the metal-based coordination complex having a specified formula. An immunogenic composition and a method for preparing it are also disclosed.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: October 11, 2022
    Assignee: THERALASE TECHNOLOGIES INC.
    Inventor: Arkady Mandel
  • Aldosterone synthase inhibitor
    Patent number: 11447491
    Abstract: The present invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and a pharmaceutically acceptable salt thereof, and in particular to the phosphate salt of (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, both having preferably an enantiomeric excess of the (R) form higher than or equal to 97%. Furthermore, the present invention relates to pharmaceutical compositions comprising the same, their use as a medicament and in methods of treatment of diseases and disorders in humans including women of child bearing potential and pediatric patients in which aldosterone over-exposure contributes to the deleterious effects of said diseases or disorders, as well as processes for preparing said inventive compounds.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: September 20, 2022
    Assignee: DAMIAN PHARMA AG
    Inventors: Christoph Schumacher, Walter Fuhrer, Ronald Edward Steele
  • Antibacterial agents: dual-targeted RNA polymerase inhibitors
    Patent number: 11447502
    Abstract: The invention provides bipartite, dual-targeted inhibitors of bacterial RNA polymerase having the general structural formula (I): X-?-Y (I) wherein X is an moiety that binds to the Rif target of a bacterial RNA polymerase; Y is a moiety that binds to the bridge-helix N-terminus target of a bacterial RNA polymerase; and is a covalent bond or a linker. The invention also provides compositions comprising such compounds, methods of making such compounds, and methods of using said compounds. The invention has applications in control of bacterial gene expression, control of bacterial growth, antibacterial chemistry, and antibacterial therapy.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: September 20, 2022
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Richard H. Ebright, Yon W. Ebright, Chih-Tsung Lin
  • Treatment of fungal infections using dabigatran etexilate
    Patent number: 11446286
    Abstract: A method of treating fungal infections using dabigatran etexilate is provided. The method can include administering a therapeutically effective amount of dabigatran etexilate to a subject in need thereof. In an embodiment, dabigatran etexilate may be effective as a broad-spectrum antifungal agent and may be used to treat infections resulting from a wide array of fungal pathogens. In an embodiment, dabigatran etexilate may be administered to treat either a topical or systemic fungal infection.
    Type: Grant
    Filed: February 28, 2022
    Date of Patent: September 20, 2022
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mahmoud Kandeel Elsayed, Naser Abdullah Alhumam, Abdulla Yousef Al-Taher
  • Process for the preparation of eribulin mesylate intermediate
    Patent number: 11447499
    Abstract: The present application provides improved processes for the synthesis of eribulin intermediate, which generally comprise the steps of: a) De-protecting the eribulin-enone (compound 1) in tetrahydrofuran by using TBAF solution, buffered with imidazole HCl in the presence of molecular sieve and sodium sulphate to get an insitu mixture of eribulin-dione diastereomer at C12 carbon (compound 2). Then ketalization may be performed of eribulin-dione insitu intermediate containing mixture of diastereomer at C12 carbon (compound 2) with PPTS in dichloromethane to yield eribulin-diol (compound 3).
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: September 20, 2022
    Assignee: RK PHARMA INC.
    Inventors: Ravishanker Kovi, Jayaraman Kannappan, Shivnath Sahebrao Patil
  • Process for the preparation of dexmethyl phenidate hydrochloride
    Patent number: 11440882
    Abstract: Disclosed herein a process for the preparation of highly pure dexmethylphenidate hydrochloride (Formula-I) which comprises the steps of neutralization of dl-threomethylphenidate hydrochloride to dl-threo methylphenidate; subsequent resolution of dl-threo methylphenidate using amino acid or its derivatives as chiral resolution agent to yield dexmethylphenidate salt; hydrolysis of the salt and further conversion of dexmethylphenidate into its hydrochloride salt.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: September 13, 2022
    Assignee: HARMAN FINOCHEM LIMITED
    Inventors: Vijay Trimbak Kadam, Nareesh Saranapu, Santosh Uttamrao Chavan, Harpreet Singh Minhas, Gurpreet Singh Minhas
  • Water soluble fluorescent or colored dyes and methods for their use
    Patent number: 11434374
    Abstract: Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I): including stereoisomers, salts and tautomers thereof, R1, R2, R3, L1, L2, L3, L4, L5, L6, M1, M2, A, q, w and n are as defined herein. Methods associated with preparation and use of such compounds are also provided.
    Type: Grant
    Filed: March 2, 2021
    Date of Patent: September 6, 2022
    Assignee: Sony Corporation
    Inventors: Tracy Matray, Hesham Sherif, C. Frederick Battrell
  • Preparation of 3-hydroxy-3,6-dimethylhexahydrobenzofuran-2-one and derivatives thereof
    Patent number: 11434216
    Abstract: The present invention relates to the synthesis of intermediate compounds which can be used in the synthesis of mint lactone and related compounds, including 3,6-dimethylhexahydrobenzofuran-2-ones, isomers, and other derivatives.
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: September 6, 2022
    Assignee: P2 SCIENCE, INC.
    Inventors: Patrick Foley, Yonghua Yang, Tania Salam
  • Compounds and methods for the treatment of neurodegenerative diseases
    Patent number: 11434198
    Abstract: Novel compounds of formula (II) are disclosed. Compounds of formula (II) comprise ornithine derivatives or compounds that can metabolize under physiological conditions to ornithine. The pH and plasma stability of compounds of formula (II) is also described. Also disclosed are methods for the treatment of neurodegenerative diseases such as Alzheimer's Disease using compounds of formula (II).
    Type: Grant
    Filed: March 22, 2021
    Date of Patent: September 6, 2022
    Assignee: Resilio Therapeutics, LLC
    Inventors: Francis Xavier Tavares, Michael Peter Vitek
  • Salt forms of a complement component C5A receptor
    Patent number: 11427541
    Abstract: Provided herein are salt forms of a complement component 5a receptor having the formula of Compound 1 Also provided herein are pharmaceutical compositions and methods of treatment using the salt forms of Compound 1, described herein.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: August 30, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: Rajinder Singh, Kwok Yau, Yibin Zeng, Penglie Zhang, Rebecca M. Lui, Ju Yang, Howard S. Roth
  • Form of isoquinoline sulfonamide
    Patent number: 11427546
    Abstract: A stable crystal of a salt of N—[(R)-1-{(S)-2-hydroxy-2-phenylpropylamino}propan-2-yl]isoquinoline-6-sulfonamide may have desirable properties for a pharmaceutical drug substance, and more specifically N—[(R)-1-{(S)-2-hydroxy-2-phenylpropylamino}propan-2-yl]isoquinoline-6-sulfonamide dihydrochloride anhydride. A crystal of the anhydride may have characteristic peaks at 2? angles of 6.8±0.1°, 10.0±0.1°, 12.7±0.1°, 14.6±0.1°, 14.8±0.1°, 16.2±0.1°, 17.4±0.1°, 17.8±0.1°, 19.5±0.1°, 20.0±0.1°, 21.6±0.1°, 24.7±0.1°, 25.5±0.1°, 25.8±0.1°, 29.8±0.1°, 39.5±0.1°, and/or 44.9±0.1° in powder X-ray diffraction spectrum.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: August 30, 2022
    Assignee: D. WESTERN THERAPEUTICS INSTITUTE, INC.
    Inventors: Hiroyoshi Hidaka, Kengo Sumi, Takashi Izuhara
  • Organotin catalysts in esterification processes of furan-2,5-dicarboxylic acid (FDCA)
    Patent number: 11420952
    Abstract: Sugar-based mono and diesters are prepared by esterification of 2,5-furan-dicarboxylic acid (FDCA) with an alcohol in the presence of low loadings of a homogeneous organotin (IV) catalyst.
    Type: Grant
    Filed: February 3, 2021
    Date of Patent: August 23, 2022
    Assignees: Archer Daniels Midland Company, DUPONT INDUSTRIAL BIOSCIENCES USA, LLC
    Inventors: Kenneth Stensrud, Stuart Fergusson
  • Heterocyclic compound
    Patent number: 11401264
    Abstract: The present invention provides a heterocyclic compound having an activity to promote the maturation of a cardiomyocyte. A compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof has an activity to promote the maturation of a cardiomyocyte, and is useful as a cardiomyocyte maturation promoter.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: August 2, 2022
    Assignee: Orizuru Therapeutics, Inc.
    Inventors: Yoshinori Yoshida, Kenji Miki, Akira Kaieda, Shigeru Kondo, Hiroshi Nara, Yoshinori Ikeura
  • Small molecule activators of Parkin enzyme function
    Patent number: 11401255
    Abstract: The present disclosure relates to compounds for activating the enzymatic activity of an E3 ubiquitin ligase and methods for treating a disease or disorder in a subject with diminished E3 ubiquitin ligase enzymatic activity. In some embodiments, the present disclosure provides a compound of Formula (I) or a compound of Formula (II) or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: August 2, 2022
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Wolfdieter Springer, Fabienne C. Fiesel, Thomas R. Caulfield